Needham analyst Michael Matson (NYSE:MATX) maintained a Buy rating on Teleflex (NYSE:TFX) Inc on Tuesday, setting a price target of $425, which is approximately 18.31% above the present share price of $359.24.
Matson expects Teleflex Inc to post earnings per share (EPS) of $1.78 for the fourth quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in Teleflex, with an average price target of $435.33.
The analysts price targets range from a high of $485 to a low of $391.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $713.47 million and a net profit of $140.11 million. The company's market cap is $16.81 billion.
According to TipRanks.com, Needham analyst Michael Matson is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 16.8% and a 64.86% success rate.
Teleflex, Inc. provides medical technology products which enables healthcare providers to improve patient outcomes and enhance patient and provider safety. The company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates through the following business segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM. The Americas segment engages in the sales of interventional urology products. The EMEA engages in the sales of urology products. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. Teleflex was founded in 1943 and is headquartered in Wayne, PA.